Literature DB >> 26808039

Resuscitative endovascular balloon occlusion of the aorta might be dangerous in patients with severe torso trauma: A propensity score analysis.

Junichi Inoue1, Atsushi Shiraishi, Ayako Yoshiyuki, Koichi Haruta, Hiroki Matsui, Yasuhiro Otomo.   

Abstract

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a key procedure in early trauma care that provides hemorrhage control in hemodynamically unstable torso trauma patients. However, the clinical efficacy of REBOA remains uncertain. The objective of this study was to estimate the efficacy of REBOA in surgically treated severe torso trauma patients.
METHODS: We obtained data from the nationwide trauma registry in Japan (the Japan Trauma Data Bank) for trauma subjects who had undergone emergency surgery or transcatheter embolization against torso trauma. A logistic regression analysis estimated a propensity score to predict REBOA use from available predictors of in-hospital mortality. We then used a propensity score matching analysis to compare in-hospital mortality and door-to-primary surgery time in subjects who underwent REBOA and those who did not. In addition, we used an instrumental variable method to adjust for unmeasured confounding variables as a sensitivity analysis.
RESULTS: Overall, 12,053 of the 183,457 trauma patients registered in the Japan Trauma Data Bank were eligible based on selection criteria. Propensity score matching selected 625 patients each for the with-REBOA and without-REBOA groups. The in-hospital mortality was significantly higher in subjects who underwent REBOA (61.8% vs. 45.3%; absolute difference, +16.5%; 95% confident interval, +10.9% to +22.0%). Door-to-primary surgery time was shorter in subjects who underwent REBOA than in those who did not (97 minutes vs. 110 minutes; absolute difference, -14 minutes; 95% confidence interval, -25 minutes to -3 minutes). The sensitivity analysis with the instrumental variable method did not alter the results and estimated nonsignificantly higher in-hospital mortality in REBOA subjects (+16.4%; 95% confidence interval, -0.6% to 33.3%).
CONCLUSION: This study showed an association between the use of REBOA and excess mortality in patients with hemodynamically unstable torso trauma that had a median door-to-primary surgery time of 97 minutes. Further observational studies with detailed REBOA data are necessary to assess whether selected trauma subgroups could benefit from REBOA. LEVEL OF EVIDENCE: Therapeutic study, level III.

Entities:  

Mesh:

Year:  2016        PMID: 26808039     DOI: 10.1097/TA.0000000000000968

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  38 in total

Review 1.  A systematic review of propensity score methods in the acute care surgery literature: avoiding the pitfalls and proposing a set of reporting guidelines.

Authors:  T L Zakrison; P C Austin; V A McCredie
Journal:  Eur J Trauma Emerg Surg       Date:  2017-03-24       Impact factor: 3.693

2.  Feasibility of REBOA-Resuscitative Endovascular Balloon Occlusion of the Aorta-in Trauma-Related Noncompressible Torso Hemorrhage at Two Metropolitan Trauma Centers.

Authors:  Glenn Ryan; Kate Swift; Frances Williamson; Elissa Scriven; Olivia Zheng; Robert Eley
Journal:  Ochsner J       Date:  2018

3.  Resuscitative endovascular balloon occlusion of the aorta: what is the optimum occlusion time in an ovine model of hemorrhagic shock?

Authors:  V A Reva; Y Matsumura; T Hörer; D A Sveklov; A V Denisov; S Y Telickiy; A B Seleznev; E R Bozhedomova; J Matsumoto; I M Samokhvalov; J J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2016-10-13       Impact factor: 3.693

4.  Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine.

Authors:  Aaron M Williams; Umar F Bhatti; Isabel S Dennahy; Kiril Chtraklin; Panpan Chang; Nathan J Graham; Basil M Baccouche; Shalini Roy; Mohammed Harajli; Jing Zhou; Vahagn C Nikolian; Qiufang Deng; Yuzi Tian; Baoling Liu; Yongqing Li; Gregory L Hays; Julia L Hays; Hasan B Alam
Journal:  J Vis Exp       Date:  2018-08-24       Impact factor: 1.355

5.  Outcomes of abdominal trauma patients with hemorrhagic shock requiring emergency laparotomy: efficacy of intra-aortic balloon occlusion.

Authors:  Kosei Kunitatsu; Kentaro Ueda; Yasuhiro Iwasaki; Shinji Yamazoe; Takafumi Yonemitsu; Yu Kawazoe; Syuji Kawashima; Naoaki Shibata; Seiya Kato
Journal:  Acute Med Surg       Date:  2016-05-10

Review 6.  The utilization of resuscitative endovascular balloon occlusion of the aorta: preparation, technique, and the implementation of a novel approach to stabilizing hemorrhage.

Authors:  Dong Hun Kim; Sung Wook Chang; Junichi Matsumoto
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 7.  [Resuscitative endovascular balloon occlusion of the aorta : Option for incompressible trunk bleeding?]

Authors:  J Knapp; M Bernhard; T Haltmeier; D Bieler; B Hossfeld; M Kulla
Journal:  Anaesthesist       Date:  2018-04       Impact factor: 1.041

8.  Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Severe Torso Trauma in Japan: A Descriptive Study.

Authors:  Shokei Matsumoto; Kei Hayashida; Taku Akashi; Kyoungwon Jung; Kazuhiko Sekine; Tomohiro Funabiki; Takashi Moriya
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

9.  Traumatic brain injury may worsen clinical outcomes after prolonged partial resuscitative endovascular balloon occlusion of the aorta in severe hemorrhagic shock model.

Authors:  Aaron M Williams; Umar F Bhatti; Isabel S Dennahy; Nathan J Graham; Vahagn C Nikolian; Kiril Chtraklin; Panpan Chang; Jing Zhou; Ben E Biesterveld; Jonathan Eliason; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2019-03       Impact factor: 3.313

10.  The effect of prehospital intravenous access in traumatic shock: a Japanese nationwide cohort study.

Authors:  Hiroki Nagasawa; Keita Shibahashi; Kazuhiko Omori; Youichi Yanagawa
Journal:  Acute Med Surg       Date:  2021-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.